Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 50 21 versus EMOQUETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 50 21 versus EMOQUETTE.
DEMULEN 1/50-21 vs EMOQUETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.
None Documented
None Documented
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Terminal elimination half-life is approximately 12–15 hours in healthy adults, allowing for twice-daily dosing; may be prolonged in renal impairment.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Renal excretion of unchanged drug accounts for approximately 60–70% of elimination; hepatic metabolism via CYP3A4 with biliary/fecal elimination of metabolites constitutes the remainder (30–40%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive